EP1173207A2 — Miotic agents and hypertonic agents containing ophthalmic compositions
Assigned to Farmigea SpA · Expires 2002-01-23 · 24y expired
What this patent protects
Ophthalmic compositions able to reduce the impairments of the visual function (like halos, glare and reduction of the night and twilight vision) resulting from keratectomy operations carried out both with laser and by conventional techniques, from intraocular lens implantation (c…
USPTO Abstract
Ophthalmic compositions able to reduce the impairments of the visual function (like halos, glare and reduction of the night and twilight vision) resulting from keratectomy operations carried out both with laser and by conventional techniques, from intraocular lens implantation (cataract surgery) and also resulting from various chronic pathologies affecting the anterior segment of the eyeball, such as the degenerations of the corneal tissue, which compositions contain one or more miotic agents, such as cholinomimetic active agents and cholinesterase inhibitors, in combination with one or more hypertonic agents, such as sulfacetamide and derivatives thereof, sodium chloride, glucose and glycerol.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.